metoprolol succinate + nebivolol

Metoprolol succinate + nebivolol is a combination of two beta-adrenergic receptor antagonists (beta-blockers) used primarily for the management of hypertension and other cardiovascular conditions. Metoprolol succinate is a cardioselective beta-1 blocker that reduces heart rate, cardiac output, and blood pressure by blocking beta-1 adrenergic receptors in the heart. Nebivolol is also a highly selective beta-1 blocker but has additional vasodilatory properties mediated by nitric oxide release from endothelial cells. Both drugs lower blood pressure effectively; however, nebivolol may offer additional benefits such as improved endothelial function and reduced oxidative stress compared to traditional beta-blockers like metoprolol[2][3][5]. This combination would theoretically provide additive or complementary antihypertensive effects through dual mechanisms—cardioselective blockade (metoprolol) and vasodilation with antioxidant effects (nebivolol). There are no known significant pharmacological interactions between these two agents when co-administered[1][4].

Other names

metoprolol succinate and nebivololmetoprolol + nebivolol